Chilbear,

I too am pleased that the company has resolved the lawsuit brought about by an Agreement JAGH executed prior to the reverse merger; perhaps this was the reason for the delay in filing the 10Q on time. However, that does not alleviate the concern I have regarding Cardiogenics continued failure to inform on the head-to-head study and the likely slippage soon to be announced on filing the 510K application with the FDA.

As you know, this past February Cardiogenics announced a new timeline stating IRB approval was expected "by May 2011" and that patients would begin enrolling in this 45 day "comparative trial" of Siemens ADVIA Centaur device and Cardiogenics QL Care Analyzer upon receipt of such IRB approval. With successful results from this four hospital study, Cariogenics informed it would finalize protocols and start the trials required for a 510K application to the FDA "during early Q3 2011" to be completed within two months.

At the Spring Growth Stock Conference in San Francisco in May 2011, Dr Gawad presented a commercialization schedule that confirmed the above information and offered in addition that during Q4 2011 the FDA clinical trials would be completed and the 510K application would be filed with the FDA.

I have no confidence that Cardiogenics will meet these publicly stated timelines.

Ante